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BACKGROUND & AIMS: Linaclotide is a minimally
absorbed agonist of guanylate cyclase-C (GUCY2C or GC-C)
that reduces symptoms associated with irritable bowel syn-
drome with constipation (IBS-C). Little is known about the
mechanism by which linaclotide reduces abdominal pain in
patients with IBS-C. METHODS: We determined the ef-
fects of linaclotide on colonic sensory afferents in healthy
mice and those with chronic visceral hypersensitivity. We
assessed pain transmission by measuring activation of
dorsal horn neurons in the spinal cord in response to
noxious colorectal distention. Levels of Gucy2c messenger
RNA were measured in tissues frommice using quantitative
reverse transcription polymerase chain reaction and in situ
hybridization. We used human intestinal cell lines to
measure release of cyclic guanosine-30,50-monophosphate
(cGMP) by linaclotide. We performed a post-hoc analysis of
data from a phase III, double-blind, parallel-group study in
which 805 patients with IBS-C were randomly assigned to
groups given an oral placebo or 290 mg linaclotide once
daily for 26 weeks. We quantiﬁed changes in IBS-C symp-
toms, including abdominal pain. RESULTS: In mice,
linaclotide inhibited colonic nociceptors with greater efﬁ-
cacy during chronic visceral hypersensitivity. Intra-colonic
administration of linaclotide reduced signaling of noxious
colorectal distention to the spinal cord. The colonic mu-
cosa, but not neurons, was found to express linaclotide’s
target, GC-C. The downstream effector of GC-C, cGMP,
was released after administration of linaclotide and also
inhibited nociceptors. The effects of linaclotide were lost in
Gucy2c/ mice and prevented by inhibiting cGMP trans-
porters or removing the mucosa. During 26 weeks of
linaclotide administration, a signiﬁcantly greater percent-
age of patients (70%) had at least a 30% reduction in
abdominal pain compared with patients given placebo
(50%). CONCLUSIONS: We have identiﬁed an analgesic
mechanism of linaclotide: it activates GC-C expressed
on mucosal epithelial cells, resulting in the production
and release of cGMP. This extracellular cGMP acts on
and inhibits nociceptors, thereby reducing nociception.We also found that linaclotide reduces chronic
abdominal pain in patients with IBS-C.
Keywords: CVH; CRD; Signaling Transduction; Analgesia.
rritable bowel syndrome (IBS) is a prevalent chronicIfunctional gastrointestinal disorder affecting 7%14%of
the North American population.1 IBS is characterized by
abdominal pain or discomfort associatedwith altered bowel
habits and is subclassiﬁed as IBS with constipation (IBS-C),
IBSwith diarrhea, and alternating/mixed IBS.2Up to 33% of
IBS patients have IBS-C, which places a considerable
ﬁnancial burden on society3 and negatively impacts the
quality of life of those affected.4 Abdominal pain is the key
clinical feature and the most difﬁcult symptom to treat in
patients with IBS.5 Given the limited treatments currently
available for patients with IBS-C, additional therapeutic
options for abdominal pain relief are urgently needed.
Linaclotide, a synthetic, minimally absorbed, 14-amino
acid peptide, is a guanylate cyclase-C (GC-C) agonist
related to guanylin anduroguanylin,members of a family of
naturally occurring peptide hormones (Supplementary
Figure 1).6 These hormones regulate intestinal ﬂuid and
electrolyte homeostasis and, thereby, bowel function
through GC-Cmediated production of cyclic-guanosine-
30,50-monophosphate (cGMP).7 Linaclotide acts via the
same mechanism as the endogenous hormones, through
binding and activatingGC-C located on the luminal surface
of intestinal epithelial cells. This interaction elevates intra-
cellular and extracellular levels of cGMP, inducing ﬂuid
secretion and accelerating intestinal transit in animal
models.8–10 In addition, linaclotide has been shown to elicit
anti-hyperalgesic effects in several animal models of visceral
pain.11 These pharmacological effects of linaclotide have
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linaclotide accelerated colonic transit and improved
abdominal pain and constipation associated with IBS-
C12–14 and chronic idiopathic constipation.15–17
However, the exact mechanism by which linaclotide
reduces abdominal pain remains unclear. In preclinical
studies, anti-nociceptive actions have not been previously
described for either guanylin or uroguanylin, and the anti-
hyperalgesic effects of linaclotide exhibited in several
distinct models of visceral pain are not attributable to
alterations in colonic compliance.11 Although the patho-
physiology of IBS is not completely understood, hallmarks
of IBS include allodynia and hyperalgesia to mechanical
events within the intestine.18–20 As mechanical hypersen-
sitivity of colonic afferents is implicated in the develop-
ment and maintenance of visceral pain in IBS,19–21 we
hypothesized that linaclotide and its downstream effector,
intestinal epithelial cellderived cGMP, might be
responsible for the inhibition of colonic nociceptors.
We speciﬁcally targeted high-threshold nociceptive af-
ferents in the splanchnic pathway, as we have shown they
normally respond to noxious levels of colonic distention/
contraction.22,23 They also become hypersensitive23 and
hyperexcitable24,25 in models of chronic visceral pain,
which translates to increased signaling of noxious colo-
rectal distention (CRD) within the thoracolumbar spinal
cord.26 We have shown that speciﬁc functional deﬁcits in
these afferents translate to reduced sensory responses to
noxious CRD in whole-animal studies.22,27 Most recently,
we have shown that alterations in peripheral blood
mononuclear cell supernatants from IBS patients correlate
with abdominal pain intensity and frequency, and evoke
mechanical hypersensitivity of colonic nociceptors.21
Here, our data show that linaclotide inhibits colonic
nociceptors in vitro and in vivo, and that the efﬁcacy of
this inhibitory effect is greatest during chronic visceral
hypersensitivity (CVH). Correspondingly, in a new post-
hoc analysis of data from a 26-week phase III clinical
trial, we show that oral administration of linaclotide
signiﬁcantly increases the percentage of patients with
clinically meaningful improvement in abdominal pain, as
speciﬁed in the recent US Food and Drug Administration
guidance for IBS clinical trials28 compared with placebo.
Overall, our data reveal a unique analgesic mechanism of
action that suggests linaclotide is able to exert beneﬁcial
effects on abdominal sensory symptoms, independent of
improvements in bowel frequency.Methods
For detailed descriptions of the methodology used,
please see the Supplementary Material.Model of CVH
Intra-colonic trinitrobenzene-sulfonic acid (TNBS; 130
mL/mL in 30% ethanol, 0.1-mL bolus) was administered as
described previously.23 TNBS-treated mice were allowed to
recover for 28 days, at which stage inﬂammation had resolvedand chronic colonic afferent mechanical hypersensitivity was
evident.23 These mice are termed CVH mice.In Vitro Electrophysiology and Pharmacology
Splanchnic colonic afferents recordings were made from
C57BL/6 healthy, CVH mice or GC-C null (Gucy2c/) mice29
using standard protocols.22,23,30 High-threshold splanchnic
nociceptors were investigated in intact colonic preparations and
in those where the mucosa had been removed.CRD and Phosphorylated MAP Kinase ERK
1/2 Immunohistochemistry
Mice received an enema of either saline or linaclotide
(1000 nM). Five minutes later, under anesthesia, a 4-cm CRD
balloon catheter was inserted transanally into healthy or CVH
mice.26 After regaining consciousness, CRD was performed
(80 mmHg for 10 seconds, then deﬂated for 5 seconds and
repeated 5 times). After sacriﬁce via anesthetic overdose, mice
underwent ﬁxation by transcardial perfusion and the thor-
acolumbar (T10L1) spinal cord was removed and cry-
oprotected. Frozen sections were cut and incubated with
monoclonal rabbit antiphosphorylated MAP kinase ERK 1/2
(pERK) with AlexaFluorR488 used for visualization.Determination of GC-C Expression With
Quantitative Reverse Transcription
Polymerase Chain Reaction and In Situ
Hybridization
Quantitative polymerase chain reaction was performed
using mouse-speciﬁc Gucy2c and glyceraldehyde-3-phosphate
dehydrogenase Taqman probes on complementary DNAs syn-
thesized from total RNAs extracted from a panel of mouse tis-
sues. For in situ hybridization, sections were hybridized
overnight at 55C with either 35S-labeled complementary RNA
anti-sense or sense probes to Gucy2c.cGMP Efﬂux Studies in Human Intestinal
Caco-2 Cells
Cells were grown in monolayers and stimulated for 1 hour
with linaclotide (1000 nM) in the presence or absence of the cGMP
transporter inhibitor probenecid (0.5 mM or 2 mM). Samples
from the basolateral chambers were collected and cGMP concen-
trations determined by liquid chromatography mass spectrometry.Contractility Studies
Electrical ﬁeld stimulation was applied to colonic tissues
in the presence and absence of linaclotide or membrane perme-
able 8-bromo-cGMP. Contraction amplitude was compared be-
tween each condition.Phase III Clinical Trial
The current results are from a post-hoc efﬁcacy analysis
of a phase III, double-blind, parallel-group, placebo-controlled
trial that randomized 805 IBS-C patients to placebo or 290 mg
oral linaclotide once daily for a 26-week treatment period. The
current efﬁcacy analysis are based on a responder end point for
abdominal pain, speciﬁed as part of a co-primary end point
recommended in the May 2012 US Food and Drug Adminis-
tration ﬁnal guidance for industry on the clinical evaluation of
products for IBS,28 deﬁned as a 30% improvement from
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December 2013 LINACLOTIDE REDUCES NOCICEPTION AND PAIN 1337baseline in average daily worst abdominal pain score.28 We pre-
sent, for the ﬁrst time, an evaluation of this abdominal pain
responder end point for each week of the 26-week treatment
period, comparing treatment and control groups.=
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inal pain in IBS-C patients17 via an inhibitory action on
colonic nociceptors. In order to test this hypothesis in
mice, we performed in vitro single-unit afferent re-
cordings. First, we investigated if linaclotide affected the
mechanosensitivity of colonic nociceptors from healthy
mice. We found that 1001000 nM linaclotide applied to
the surface of the mucosal epithelium signiﬁcantly and
dose-dependently decreased healthy colonic nociceptor
activity, reducing responses to mechanical stimulation by
49% at the highest concentration tested (Figure 1Ai, Aii).
Nociceptor mechanosensitivity was similarly reduced by
linaclotide in response to noxious circular stretch
(Supplementary Figure 2A, B, and C).
We then asked if these linaclotide-induced anti-noci-
ceptive effects were maintained, or indeed augmented in
chronic visceral pain, such as that suffered by IBS pa-
tients.19 This question was assessed in an animal model of
chronic visceral pain, where colonic nociceptor mechanical
hypersensitivity23 and colonic mechanical hyperalgesia
and allodynia are evident long after resolution of TNBS-
induced colitis.31,32 We found that colonic nociceptors
in the CVH model displayed pronounced mechanical hy-
persensitivity and that linaclotide signiﬁcantly reduced
their mechanosensitivity (Figure 1Bi and Bii), showing
signiﬁcant reductions at 30 nM and reversing the chronic
visceral mechanical hypersensitivity, with a maximal
reduction of 63% at 1000 nM (Figure 1Bi and Bii). Lina-
clotide’s inhibitory effect was greatly enhanced in CVH
compared with healthy nociceptors (Figure 1C).. Linaclotide, a GC-C agonist, inhibits colonic nociceptors with greater efﬁc
antly reduced after increasing concentrations of linaclotide applied to the
t 100 nM, 300 nM, and 1000 nM signiﬁcantly reduced colonic nociceptor m
, one-way analysis of variance [ANOVA], Bonferroni-post hoc). (ii) Single-
olonic nociceptor in response to mechanical application of a 2-g von Frey h
inute application of linaclotide (1000 nM). Top panel shows the instantaneou
oval of the vfh. (B) (i) In a model of CVH, nociceptors are potently and conc
e at 30 nM, 100 nM, 300 nM, and 1000 nM signiﬁcantly reduced the mech
es (***P< .001, n ¼ 10 afferents, one-way ANOVA, Bonferroni post-hoc tes
or after application of linaclotide (1000 nM). (C) Change in mechanosen
d with their respective baseline responses. Linaclotide caused signiﬁcantly
< .001) in CVH nociceptors than healthy nociceptors (n ¼ 12 healthy, n ¼
inhibits colonic nociceptors with greater efﬁcacy in CVH. (i) The endogenous
s at each concentration signiﬁcantly reduces healthy colonic nociceptor me
eline (***P < .001, n ¼ 7 afferents). (ii) Inhibition of healthy murine colonic
(E) CVH nociceptors are concentration-dependently inhibited by uroguanylin
). (ii) Inhibition of CVH murine colonic nociceptor responsiveness after uro
at 100nM (**P < .01), 300 nM (**P < .01), 1000 nM (**P < .01), and 3000 n
d with their respective baseline responses (n ¼ 7 healthy, n ¼ 9 CVH).Endogenous GC-C Agonist Uroguanylin Also
Inhibits Colonic Nociceptors
In order to determine whether these anti-nociceptive
effects were speciﬁc to linaclotide or could be induced by
other GC-C agonists, we also studied the endogenous
hormone uroguanylin. Application of uroguanylin to the
colonic mucosal surface caused signiﬁcant, dose-dependent
inhibition of healthy colonic nociceptors (Figure 1Di and
Dii). This effect was greatly enhanced in CVH (Figure 1Ei,
Eii, and F). Overall, these ﬁndings indicate the GC-C ago-
nists linaclotide and uroguanylin are able to inhibit colonic
nociceptor function and reverse CVH.Linaclotide Reduces Processing of Noxious
CRD in the Thoracolumbar Spinal Cord
In Vivo
Because linaclotide inhibits colonic nociceptors, as
shown here, and inhibits pain responses in vivo,11 we
hypothesized this inhibition should correspondingly
reduce signaling of noxious CRD within the spinal cord
in vivo. We identiﬁed activated neurons in the dorsal horn
(DH) of the thoracolumbar spinal cord in response to
noxious CRD by pERK immunoreactivity (IR).26 In
healthy mice, intra-colonic administration of 1000 nM
linaclotide resulted in signiﬁcantly fewer pERK-IR DH
neurons in the thoracolumbar spinal cord after noxious
CRD compared with saline administration (Figure 2A, D,
and E).
In response to noxious CRD, CVH mice displayed
greater numbers of pERK-IR DH neurons than healthy
mice, which corresponds with the extent of colonic noci-
ceptor mechanical hypersensitivity observed in vitro. In
CVH mice, linaclotide pretreatment resulted in a dramatic
reduction in the number of pERK-IR DH neurons in the
thoracolumbar spinal cord after noxious CRD (Figure 2B,
D, and F). Overall, these results suggest that linaclotide
reduces nociceptive signaling and reverses chronic visceral
mechanical hypersensitivity in vivo. This ﬁnding correlates
with our in vitro nociceptor ﬁndings and potentiallyacy in CVH. (A) (i) Healthy colonic nociceptor mechanosensitivity
mucosal epithelium for 5 minutes at each concentration. Lina-
echanosensitivity compared with baseline (***P < .001; n ¼ 12
unit recording showing action potential discharge of a healthy
air ﬁlament (vfh) at baseline. Afferent responsiveness is reduced
s frequency of action potential ﬁring. Arrows indicate application
entration-dependently inhibited by linaclotide. Concentrations of
anical response of colonic nociceptors compared with baseline
ts). (ii) Single-unit recordings showing potent inhibition of a CVH
sitivity induced by linaclotide in healthy and CVH nociceptors
more inhibition at 30 nM (*P < .05), 100 nM, 300 nM, and 1000
10 CVH, 2-way ANOVA, Bonferroni post-hoc tests). (D) Uro-
GC-C agonist uroguanylin applied to the mucosal epithelium for
chanosensitivity at 300 nM,1000 nM, and 3000 nM compared
nociceptor responsiveness after uroguanylin (3000 nM) admin-
at 100 nM, 300 nM, 1000 nM, and 3000 nM (***P < .001, n ¼ 9
guanylin (3000 nM). (F) Uroguanylin causes signiﬁcantly more
M (*P < .05) in CVH nociceptors relative to healthy nociceptors
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clinical trial analysis.Expression of GC-C in Mouse Tissue
To further elucidate the site and mechanism of
action of linaclotide, we used quantitative reverse tran-
scription polymerase chain reaction and found that GC-C
is predominantly expressed within the gastrointestinal
tract, with low or undetectable expression in other tissues
(Figure 3A). We conﬁrmed these ﬁndings with in situ
hybridization (Figure 3B) and found abundant GC-C
expression in the colonic mucosa (Figure 3C). Although
previous studies have also shown GC-C expression local-
ized to speciﬁc midbrain neurons,33 we found that GC-C
expression was not detectable in key sensory structures,
such as dorsal root ganglia and spinal cord neurons
(Figure 3D). In order to conﬁrm that inhibition of colonic
nociceptors by linaclotide was GC-C dependent, we per-
formed mechanosensitivity studies using GC-C/ mice.
Baseline colonic nociceptor responses were similar to
those observed in normal healthy mice; however, the
linaclotide-induced inhibition was completely lost
(Figure 4A). Taken together, these data suggest that the
anti-nociceptive effect of linaclotide is dependent on local
activation of GC-C on intestinal epithelial cells. We also
show that linaclotide does not alter colonic muscle
contractility, and the membrane permeably 8-bromo-
cGMP does reduce contractility (Figure 4B).Linaclotide Stimulates cGMP Release, Which
Inhibits Colonic Nociceptors
Linaclotide, like other GC-C agonists, elevates
intracellular cGMP, which acts as a second messenger in
the downstream mediation of intestinal ﬂuid secre-
tion.6,34,35 Linaclotide acts locally with very low systemic
bioavailability,34 so is unlikely to activate intestinal noci-
ceptors directly. However, cGMP is released from
intestinal epithelial cells upon GC-C activation,9,10 and
could serve as a downstream mediator for linaclotide-
induced effects on colonic nociceptors. In order to
further investigate this role of extracellular cGMP, we used
a human intestinal Caco-2 cell line, which is known to
express GC-C, and stimulated the cells with linaclotide.
This stimulation resulted in a signiﬁcant transporter-
dependent basolateral release of cGMP out of the cells,
which was concentration-dependently decreased by the
cGMP transporter inhibitor, probenecid (Figure 4C).
Correspondingly, in colonic nociceptor recordings,
linaclotide-induced inhibition of mechanosensitivity
(Figure 4Di) was prevented by probenecid pretreatment
(Figure 4Dii). This ﬁnding suggests extracellular cGMP
derived from intestinal epithelial cells mediates
linaclotide-induced inhibition of colonic nociceptors.
To conﬁrm this hypothesis, colonic nociceptor recordings
were performed in preparations where the mucosal
epithelium had been removed, to abolish the source of
GC-C. In these studies, baseline nociceptormechanosensitivity was normal, however, linaclotide-
induced inhibition was signiﬁcantly diminished in prep-
arations from both healthy (Figure 4Ei) and CVH mice
(Figure 4Eii).
In healthy colonic preparations, application of exoge-
nous cGMP to the colonic mucosa replicated the inhibitory
effects (Figure 5Ai and Aii) evoked by both linaclotide and
uroguanylin. In addition, exogenous cGMP caused greater
inhibition of CVH nociceptors (Figure 5Bi and Bii). In
preparations where the colonic mucosa had been removed,
the inhibitory effect of exogenous noncell permeant
cGMP was more potent, dose-dependent, and occurred at
lower concentrations of cGMP (Figure 6A, B, and C).Oral Linaclotide Reduces Abdominal Pain in
Patients With IBS-C in a Phase III Clinical
Trial
We include a new post-hoc longitudinal responder
analysis, using the US Food and Drug Administration’s
recommended abdominal responder criterion,28 from a
26-week phase III trial of oral, once-daily administration
of linaclotide vs placebo in 805 IBS-C patients. The per-
centage of patients achieving at least a 30% reduction in
abdominal pain compared with baseline was statistically
signiﬁcant and clinically meaningful for each of the 26
weeks of treatment with linaclotide compared with the
placebo. A 30% reduction in abdominal pain compared
with baseline was reported by >50% of linaclotide-treated
patients by week 3, increased to >60% of linaclotide-
treated patients by week 7, and was sustained at approx-
imately 70% of linaclotide-treated patients for the
remainder of the 26 weeks of treatment (Figure 7A).Discussion
This study provides strong evidence for a direct
analgesic mechanism of action, whereby linaclotide in-
hibits colonic nociceptors via a GC-C/extracellular cGMP
pathway, to reduce colonic nociception and abdominal
pain. This novel, previously unreported, pathway sug-
gests linaclotide is able to exert its beneﬁcial effects
directly on abdominal sensory symptoms, independent of
improvements in bowel movement frequency and
function.
We have demonstrated that linaclotide inhibits the
mechanical responsiveness of splanchnic colonic noci-
ceptors, which have high-activation thresholds to me-
chanical stimuli. This ﬁnding is important, as these
afferents have endings distributed throughout the
length of the colon,30 express large quantities of algesic
channels and receptors,21,22,27,36,37 and become me-
chanically hypersensitive23 and hyperexcitable24,25 in
various preclinical models of chronic visceral pain. These
in vitro ﬁndings translate in vivo as mice administered
linaclotide have a reduced capacity to detect noxious
CRD, as indicated by the reduction in activated DH
neurons within the thoracolumbar spinal cord. In
particular, we observed fewer activated neurons in the
Figure 2. Intra-colonic administration of linaclotide reduces nociceptive signaling in the dorsal horn of the spinal cord in response to noxious CRD.
(A) Noxious CRD (80 mmHg) in healthy mice results in activation of DH neurons in the thoracolumbar spinal cord, as indicated by pERK-IR (open
columns). In mice pretreated with intra-colonic linaclotide (1000 nM; shaded columns), signiﬁcantly fewer DH neurons are activated in the T11T12
(***P < .001) and T13L1 (***P < .001) spinal cord. One-way analysis of variance (ANOVA), healthy plus saline (N ¼ 5), healthy plus 1000 nM
linaclotide (N ¼ 3). (B) In CVH mice more DH neurons are activated by noxious CRD at baseline (closed columns). However, pretreatment with intra-
colonic linaclotide (1000 nM) signiﬁcantly reduces the number of pERK-IR DH neurons in T10T11 (*P < .05), T11T12 (***P < .001), and T13L1
(***P < .001) spinal cord (shaded columns). CVH plus saline (N ¼ 5), CVH plus 1000 nM linaclotide (N ¼ 4). (C) Schematic representation of laminae
IV in the dorsal horn of the thoracolumbar spinal cord. (D) Upper panels: In healthy mice, after noxious CRD, pERK-IR (yellow arrows) neurons were
predominantly located in lamina I and lamina V. In healthy mice pretreated with linaclotide (1000 nM) signiﬁcantly fewer pERK-IR neurons are evident
after noxious CRD (see [E] for more examples). Lower panels: In CVH mice, after noxious CRD, pERK-IR neurons were predominantly located in the
superﬁcial DH laminae III and throughout laminae IIIV. In CVH mice pretreated with linaclotide (1000 nM) signiﬁcantly fewer pERK-IR neurons are
evident after noxious CRD (see [F] for more examples).
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nation zone for nociceptive afferents and consists of
nociception-speciﬁc neurons responding to noxious in-
puts from afferent ﬁbers. Notably, the potency of thesein vitro and in vivo inhibitory effects are greatest in a
model of CVH, where linaclotide fully reversed the
chronic mechanical hypersensitivity in vitro, and lina-
clotide pretreatment in vivo reduced signaling of
Figure 3. (A) GC-C messenger RNA (mRNA) expression in mouse tissues. Determined by quantitative reverse transcription polymerase chain
reaction normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The vast majority of GC-C expression is localized in the gastroin-
testinal tract. (B) GC-C in situ hybridization in adult mouse tissues. (i) Cresyl violet (cv) staining in sections of adult mouse. (ii) In situ hybridization x-ray
ﬁlm autoradiography with GC-C receptor anti-sense (as) probes, showing a gut-speciﬁc GC-C mRNA distribution pattern in the adult mouse. GC-C
staining is abundant in the small intestine (SIn), cecum (Ce), colon (Co), and rectum (Re). (iii) Use of complementary sense (s) probes as negative
controls, revealing no labeling above background. Br, brain; H, heart; K, kidney; L, lumen; Li, liver; LN, lymph node; Lu, lung; Mu, mucosa; R, ribs; Re,
rectum; SG, salivary gland; Sk, skin; Smu, submucosa; St, stomach; Th, thymus; UB, urinary bladder; Ve, vertebrae. (C) GC-C in situ hybridization in
adult mouse colon. (i) Cresyl violet staining in a section of colon. (ii) In situ hybridization with GC-C anti-sense probes, showing GC-C mRNA
expression in the colonic mucosa. (iii) Negative control using complementary sense probes. L, lumen, Mu, mucosa, Smu, submucosa; M, muscle;
S, serosa. (D) Lack of GC-C staining in adult spinal cord and dorsal root ganglia (DRG). (i) Cresyl violet staining. (ii) In situ hybridization with GC-C anti-
sense probes, showing a lack of GC-C mRNA in the spinal cord and DRG. (iii) Negative control complementary sense probes. B, bone; BM, bone
marrow; cc, central canal; DH, dorsal horn; M, muscle; VH, ventral horn.
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normal, healthy levels.
These anti-nociceptive actions of linaclotide correlate
well with one previous preclinical study, which showedlinaclotide reduces colonic hypersensitivity in different
models of noninﬂammatory and inﬂammatory visceral
pain.11 The remarkable aspect of these ﬁndings was the
ability of linaclotide to reverse the visceral hypersensitivity
Figure 4. (A) Linaclotide-induced in-
hibition of colonic nociceptors is lost in
GC-C/ mice. Colonic nociceptors
from GC-C/ mice display normal
mechanosensory responses; howev-
er, linaclotide-induced inhibition is
completely lost (NS; P > .05, n ¼ 7,
paired t test). (B) Linaclotide does not
affect electrical ﬁeld stimulation (EFS)
induced contractions of rat colonic
tissues. EFS (8 Hz, 0.5 milliseconds,
10 V, 3 trains of 10-second width,
2-minute delay between trains)
induced colonic contractions were not
signiﬁcantly altered by prior incubation
of vehicle (n ¼ 6) or linaclotide (1000
nM; n ¼ 6) for 5 minutes. In contrast,
membrane permeable 8-bromo-
cGMP signiﬁcantly reduced contrac-
tility (***P < .001). (C) Linaclotide
stimulates release of cGMP from hu-
man intestinal Caco-2 cells. Cells
grown in monolayers were stimulated
for 1 hour with linaclotide (1000 nM) in
the presence or absence of the cGMP
transporter inhibitor probenecid (0.5
mM or 2 mM; triplicate for each
experiment). Linaclotide stimulated
cGMP production and cGMP trans-
port from the basolateral membrane,
an effect that was concentration-
dependently blocked by probenecid
treatment (***P < .001, 1-way analysis
of variance [ANOVA]). (D) Inhibiting the
cGMP transporter prevents linaclotide-
induced inhibition of colonic noci-
ceptors. (i) Nociceptors are potently
inhibited by a single dose of 1000 nM
linaclotide (***P < .001, n ¼ 12 affer-
ents, paired t test). (ii) Prior addition of
the cGMP transporter inhibitor,
probenecid (1 mM), prevented
linaclotide-induced inhibition of colonic
nociceptors (NS, P > .05, n ¼ 6,
1-way ANOVA). (E) Linaclotide-
induced inhibition of colonic noci-
ceptors requires an intact mucosal
epithelium. (i) A single dose of linaclo-
tide (1000 nM) causes pronounced
nociceptor inhibition in intact prepara-
tions from healthy mice. This inhibitory
effect is signiﬁcantly diminished in
preparations where the mucosal
epithelium has been removed (*P <
.05, n ¼ 12 mucosa intact, n ¼ 6
mucosa removed, unpaired t test). (ii)
Similarly, in CVH mice, nociceptor in-
hibition by linaclotide is signiﬁcantly
reduced in preparations where the
mucosa has been removed (***P <
.001, n ¼ 10 mucosa intact, n ¼ 6
mucosa removed, unpaired t test).
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Figure 5. (A) (i) cGMP inhibits
healthy colonic nociceptors.
Exogenous application of non–
cell permeant cGMP to the
mucosal epithelium inhibits
healthy colonic nociceptors
(*P < .05 at 50 mM and 250
mM, n ¼ 16 afferents, 1-way
analysis of variance [ANOVA],
Bonferroni post-hoc tests). (ii)
Healthy murine colonic noci-
ceptor mechanical response to
a von Frey hair ﬁlament (vfh) is
reduced after a 5-minute
application of cGMP (50 mM).
(B) (i) cGMP causes greater in-
hibition of CVH colonic noci-
ceptors. CVH nociceptors are
potently inhibited by exogenous
application of cGMP to the
mucosal epithelium at 50 mM
(*P < .05), 250 mM (**P < .01),
and 1000 mM (***P < .001,
n ¼ 18 afferents, 1-way
ANOVA, Bonferroni post-hoc
tests). (ii) Reduced CVH
murine colonic nociceptor
mechanical response to a vfh
after cGMP (50 mM).
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stress, and TNBS-induced colitis.11 Our results also
conﬁrm that linaclotide does not act to alter colonic
contractile activity in response to electrical ﬁeld simula-
tion. Overall, our newly identiﬁed mechanism of action of
linaclotide provides a rationale for linaclotide’s anti-
hyperalgesic effects in mechanistically distinct models of
visceral pain via linaclotide-induced inhibition of colonic
nociceptor peripheral endings.
These preclinical ﬁndings have translated into the
clinic; in a new analysis of a 26-week phase III clinical trial
using the recently published US Food and Drug Admin-
istration abdominal pain responder criterion,28 >50% of
linaclotide-treated IBS-C patients at week 3 reported a
30% reduction in abdominal pain compared with base-
line. This level of analgesic effect increased to >60% of
linaclotide-treated patients at week 7 and was sustained at
approximately 70% of linaclotide-treated patients for the
remainder of the 26 weeks of treatment. Previous analysis
of these data showed the mean absolute and percent
changes in abdominal pain for the linaclotide and placebo
groups over time.12 In the present study, we have evalu-
ated the percent of patients with at least 30% improve-
ment in abdominal pain on a weekly basis, data that have
not been shown previously. These ﬁndings are important,
as abdominal pain strongly correlates with IBS severity
and is one of the most difﬁcult symptoms to treat.38 Our
current ﬁndings of reduced colonic nociceptor mechano-
sensitivity in response to linaclotide provide a potential
mechanism of action underlying the improvement of
abdominal pain in patients after linaclotide treatment.Our mechanistic studies have conﬁrmed previous
studies showing that GC-C expression is found predomi-
nantly on the gastrointestinal mucosa. In addition, we
have found there is little or no GC-C expression in sensory
dorsal root ganglia neurons, and the inhibitory effect of
linaclotide on colonic nociceptors was lost in GC-C/
mice. These results conﬁrm that linaclotide inhibits
colonic nociceptors by acting on intestinal epithelial cells
via a GC-Cdependent mechanism. This linaclotide-
induced nociceptor inhibition was signiﬁcantly attenu-
ated by prior removal of the colonic mucosa in both
healthy and CVH states and by the cGMP transporter
inhibitor probenecid, which blocked linaclotide-
stimulated cGMP release from human intestinal Caco-2
cells. We also found that exogenously applied cGMP
causes nociceptor inhibition with greatest efﬁcacy in CVH,
although at higher concentrations than linaclotide.
However, by improving accessibility to nociceptor endings,
exogenous cGMP has increased efﬁcacy, exerting its anti-
nociceptive effects at lower concentrations, where dose-
dependence is also most evident. Taken together, these
ﬁndings suggest that linaclotide, rather than acting
directly on colonic nociceptors, binds and activates GC-C
on the luminal surface of intestinal epithelial cells,
resulting in increased intracellular cGMP production.
cGMP is then actively transported across the basolateral
epithelial cell membrane into the submucosal space, where
it exerts its action on nociceptors located on blood ves-
sels30,39 to inhibit their function (Figure 7B). Although
active mechanisms for transport of cGMP out of cells have
been described, cGMP is poorly diffused across cell
Figure 6. Exogenous noncell permeant cGMP causes greater inhibition at lower doses in healthy preparations where the mucosal epithelium has
been removed. (i) Exogenous application of cGMP at (Ai) 10 mM (NS, n ¼ 9, paired t test), (Bi) 50 mM (*P < .05, n ¼ 15), and (Ci) 1000 mM (NS, n ¼
14, paired t test) to the mucosal epithelium has a minimal effect on healthy nociceptors in intact preparations. (ii) In preparations where the mucosal
epithelium had been removed, where accessibility of cGMP to nociceptors is improved, cGMP caused signiﬁcant inhibition at (Aii) 10 mM (* P < .05,
n ¼ 5, paired t test), (Bii) 50 mM (***P < .01, n ¼ 10, paired t test), and (Cii) 1000 mM (***P < .01, n ¼ 9, paired t-test). (iii) cGMP-induced inhibition is
signiﬁcantly increased in mucosa removed preparations compared with intact preparations at (Aiii) 10 mM (*P < .05), (Biii) 50 mM (*P < .05), and (Ciii)
1000 mM (**P < .01). (iv) Healthy colonic nociceptor recordings in preparations where the colonic mucosa had been removed. Trace shows the
mechanical responsiveness at baseline and after 5-minute application of cGMP (Aiv: 10 mM, Biv: 50 mM, Civ: 1000 mM).
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into cells.40 Therefore, we believe the effects of cGMP on
colonic nociceptors are acting through an extracellular or
membrane target. We believe this report is the ﬁrst to
show that extracellular cGMP alters intestinal nociceptor
function and mediates peripheral analgesia. This pathway
is independent of the NO/soluble guanylate cyclase
mechanism and the resulting effects of increasing
neuronal intracellular cGMP that have been reported
previously using different pharmacological agents,41,42
including membrane permeable cGMP (8-bromo-cGMP
or CPT-cGMP).43 Additional studies to elucidate the mo-
lecular target for extracellular cGMP are ongoing.
In addition to linaclotide, the endogenous GC-C
agonist uroguanylin also inhibited colonic nociceptors.
These ﬁndings are not only consistent with those of
linaclotide, but uncover a previously unidentiﬁed anti-
nociceptive effect of uroguanylin, suggesting sensorysignaling from the colon can be modulated endogenously
via GC-C activation. A principal task of the digestive sys-
tem is to solubilize nutrients for absorption, and also
regulate ﬂuid secretion. The guanylate cyclase system is
conserved across vertebrate, nonvertebrate, and more
distant phylogenetic species.44 As uroguanylin and gua-
nylin are released after a meal, we suggest this system
might have evolved to facilitate digestion by assuring a
ﬂuid environment, while suppressing pain evoked by food-
induced distention and naturally occurring high-
amplitude intestinal contractions. We speculate that
patients with IBS-C might have alterations in the GC-C
signaling pathway, which is currently under investigation.
In conclusion, our ﬁndings demonstrate linaclotide
inhibits colonic nociceptors via a novel GC-C/extracellular
cGMP pathway to reduce nociception and abdominal
pain. These results also advance our understanding of
how the release of mediators, like cGMP, from the
Figure 7. (A) Linaclotide signiﬁcantly improves abdominal pain in patients with IBS-C. In a 26-week phase III clinical trial involving 805 IBS-C patients,
oral administration of linaclotide (290 mg) resulted in a signiﬁcant increase in the percentage of patients with a 30% improvement in abdominal pain
over baseline (US Food and Drug Administration abdominal pain responder criterion) compared with placebo each week for 26 weeks of treatment.
The percentage of patients with this level of improvement in abdominal pain was evident and separated from placebo during the ﬁrst week of
treatment, continued to increase over the ensuing 1012 weeks and was maintained throughout the remainder of the 26-week treatment period,
with a maximal sustained response in approximately 70% of linaclotide-treated patients versus approximately 50% of placebo-treated patients (**P <
.005 for each of the 26 weeks). One-way analysis of covariance at each week. (B) Proposed anti-nociceptive mechanism of linaclotide. Linaclotide, a
minimally absorbed peptide GC-C agonist, binds to GC-C expressed on the apical surface of the mucosal epithelium, leading to cGMP production.
The increase in cGMP within intestinal epithelial cells triggers a signal transduction cascade activating the cystic ﬁbrosis transmembrane conductance
regulator (CFTR) and inhibiting isoform 3 of the sodium/hydrogen exchanger. These processes lead to secretion of chloride and bicarbonate into, and
retention of sodium within the intestinal lumen, resulting in increased luminal ﬂuid secretion and an acceleration of intestinal transit. cGMP is also
released, via a transporter dependent mechanism, through the basolateral membrane of intestinal epithelial cells. This extracellular, noncell per-
meant cGMP can then act on high-threshold colonic nociceptors, which are located on blood vessels, to inhibit their mechanosensitivity and lead to
reduced nociception and reduced abdominal pain. GTP, guanosine triphosphate; PKGII, Protein kinase II.
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visceral perception. This analgesic mechanism of action of
linaclotide suggests that improvements in abdominal pain
can occur independently of improvements in bowel
function. These ﬁndings further support the therapeutic
use of linaclotide as a new option for chronic abdominal
pain in patients with IBS-C.Supplementary Material
Note: To access the supplementary material
accompanying this article, visit the online version ofGastroenterology at www.gastrojournal.org, and at http://
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Supplementary Methods
Preclinical Studies
Experiments involving animals were approved by
the Animal Ethics Committees of the Institute of Veteri-
nary and Medical Science and University of Adelaide.
CVH Model
Male C57 BL/6 mice were used in all experiments.
Colitis was induced by administration of TNBS, as
described previously.1 Brieﬂy, 13-week-old mice were
administered an intracolonic enema of 0.1 mL TNBS (130
mg/mL in 30% EtOH) via a polyethylene catheter inserted
3 cm from the anus of isoﬂurane-anesthetized mice. Mice
were then individually housed and observed daily for
changes in body weight, physical appearance, and
behavior. Histological examination of mucosal architec-
ture, cellular inﬁltrate, crypt abscesses, and goblet cell
depletion conﬁrmed TNBS-induced signiﬁcant damage by
day 3 post treatment, largely recovered by day 7, and fully
recovered at the day 28 time point. High-threshold noci-
ceptors from mice at the 28 day time point display sig-
niﬁcant mechanical hypersensitivity, lower mechanical
activation thresholds,1 and display hyperalgesia and allo-
dynia.2 As such, they are therefore termed chronic visceral
hypersensitivity (CVH) mice.
In Vitro Mouse Colonic Primary Afferent
Preparation, Recording, and Drug Addition
Age-matched mice were euthanized by CO2 inhala-
tion at days 0 (healthy) or 28 days post TNBS administra-
tion (CVH). In both cases, the colon, rectum, and attached
mesentery were removed and afferent recordings from the
splanchnic nerves performed as described previously.1,3–5
Brieﬂy, tissue was removed and pinned ﬂat, mucosal side
up, in a specialized organ bath. The colonic compartment
was superfused with a modiﬁed Krebs solution (in mM:
117.9 NaCl, 4.7 KCl, 25NaHCO3, 1.3 NaH2PO4, 1.2MgSO4
[H2O]7, 2.5 CaCl2, and 11.1 D-glucose) and bubbled with
carbogen (95% O2, 5% CO2) at a temperature of 34C.
In vitro single-unit extracellular recordings were performed
of action potentials generated by mechanical stimuli
applied to afferent ﬁber receptive ﬁelds.
Mechanoreceptor Classiﬁcation
Receptive ﬁelds were identiﬁed by systematically
stroking the mucosal surface with a still brush to activate
all subtypes of mechanoreceptors. Categorization of
afferent properties was in accordance with our previously
published classiﬁcation system.1,3–6 In short, splanchnic
serosal afferents, which are also termed vascular afferents,
have high-mechanical activation thresholds responding to
noxious distension (40 mmHg), stretch (7 g), or von Frey
hair ﬁlaments (2 g), but do not respond to ﬁne mucosal
stroking (10 mg von Frey hair).1,4,5 They express large
quantities of algesic channels and receptors (TRPV1,7
TRPA1,3,8 TRPV4,5 P2X3,
7 B1,6 NaV1.8,
9 TNFR1,10),
become mechanically hypersensitive in models of chronic
visceral pain,1 have nociceptor phenotypes, and are there-
fore referred to as “nociceptors” in this study.4,11 Baseline
mechanosensitivity was determined in response to a 2-g von
Frey hair probe stimulation of the receptive ﬁeld for 3 sec-
onds, which was then removed. This process was repeated
34 times, separated each time by 10 seconds. Mechano-
sensitivity was then retested after application of linaclotide
(1, 30, 100, 300, 1000 nM), uroguanylin (30, 100, 300, 1000,
3000 nM), and cGMP (1, 50, 250, 1000 mM). All doses of
linaclotide, uroguanylin, and cGMP were applied for 5
minutes each. We have calculated that oral treatment of
linaclotide (290 mg) in humans equates approximately to
the highest dose of linaclotide we used in the preclinical
studies (Supplementary Figure 1). Probenecid was incu-
bated for 10 minutes. Linaclotide, uroguanylin, and
cGMP were provided by Ironwood Pharmaceuticals Inc.
Probenecid was purchased from Sigma-Aldrich Inc.
(Sydney, Australia).
In all cases, test compounds were applied to the
mucosal surface of the colon for a period of 5 minutes at
each concentration via a small metal ring placed over the
receptive ﬁeld of interest. In some experiments, nocicep-
tor mechanosensitivity was determined in response to
11-g circular stretch1,5 applied across the receptive ﬁeld
in the absence and presence of linaclotide (1000 nM)
(Supplementary Figure 2). In some experiments, before
recordings commenced, the mucosal epithelium was
microdissected away from the underlying muscle layers
to determine the contribution of mucosal epithelium
GC-C expression on nociceptor mechanosensitivity in the
presence and absence of GC-C agonists and cGMP. Some
recordings were also performed in GC-C null mutant
(/) mice.12 In some experiments, the cGMP efﬂux
blocker, probenecid (1 mM), was incubated for 10 mi-
nutes before linaclotide incubation. Action potentials
were analyzed off-line using the Spike 2 wavemark
function and discriminated as single units on the basis of
distinguishable waveform, amplitude, and duration. Data
are presented as spikes/second or total number of action
potentials per response. Data are expressed as mean 
SEM. In some cases, data are presented as the change
from baseline. This is calculated by determining the
change in mechanosensitivity of individual afferents be-
tween their normal baseline response in healthy or CVH
conditions compared with their respective mechanical
response after drug addition. This difference is then
averaged across all afferents tested in the respective study
set, for a ﬁnal mean  SEM change in response from
baseline (n indicates the number of individual afferents).
Data were analyzed using Prism 5 software (GraphPad
Software, San Diego, CA), where appropriate, using either
paired or unpaired t tests and 1-way or 2-way analysis
of variance, followed by Bonferroni post-hoc tests.
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Differences between speciﬁc drug concentrations and
baseline responses were considered signiﬁcant at a level
of *P < .05; **P < .01; and ***P < .001.
CRD
Healthy or CVH mice were fasted overnight with
free access to water and a 5% glucose solution, ensuring
fecal pellets were absent from the colorectum for CRD.
Twenty-four hours later, mice were brieﬂy anesthetized
with isoﬂurane anesthetic. Mice received either a single
0.2-mL intracolonic enema of saline or linaclotide (1000
nM in 0.1M phosphate buffered saline [PBS]) via a
polyethylene catheter inserted 3 cm from the anus. Five
minutes after saline or linaclotide were administered, a 4-
cm balloon catheter was inserted into the perianal canal
and secured to the tail so that the start of the balloon sat
0.5 cm from the anal opening. The tube was secured to
the tail. The balloon catheter was attached to a sphyg-
momanometer pressure gauge and a 20-mL syringe via a
3-way stopcock. Mice were removed from the isoﬂuorane
chamber and, on regaining consciousness, the balloon was
distended for 10 seconds to a pressure of 80 mmHg
applied via the syringe. This pressure was released and the
balloon deﬂated (0 mmHg) for 5 seconds. This process was
repeated 5 times, as per our previous studies.13 After the
ﬁfth distension, mice were injected with an anesthetic
overdose (0.2 mL/250 g sodium pentobarbitone) and
within 4 minutes underwent transcardial perfuse ﬁxation
with ice-cold 4% paraformaldehyde ﬁxative. Control mice
received intracolonic administration of 0.1M PBS before
the CRD protocol (n indicates the number of animals used
per study). Our previous histological studies demonstrate
that this protocol does not overtly damage the colonic
epithelium.
Tissue Processing for Immunohistochemistry
Within 2 minutes after the ﬁnal deﬂation, mice
were administered an anesthetic overdose (0.125 mL/250 g
sodium pentobarbitone) and underwent transcardial
perfuse ﬁxation. Mice were transcardial perfused with
warm saline (0.85% physiological sterile saline) followed by
ice-cold 4% paraformaldehyde in 0.1M phosphate buffer
(Sigma-Aldrich, St Louis, MO). After transcardial perfu-
sion, thoracolumbar (T10L1) spinal cord was removed,
using the lowest rib as an anatomical marker of T13, and
post-ﬁxed for 16 hours at 4C in 4% paraformaldehyde in
0.1M phosphate buffer. After ﬁxation, dorsal root ganglion
and spinal cord were cryoprotected in 30% sucrose/phos-
phate buffer (Sigma-Aldrich) overnight at 4C and then
placed in 50% Optimal Cutting Temperature compound
(Tissue-Tek, Sakura Finetek, Torrance, CA) in 30% sucrose/
phosphate buffer solution for 7 hours, before block
freezing in 100% Optimal Cutting Temperature com-
pound. Frozen sections (15 mm) were cut using a cryostat
and placed onto saline-coated slides for ﬂuorescent
immunohistochemistry.
pERK Immunohistochemistry
Immunohistochemistry for pERK was performed in
a paired fashion, with tissue from healthy and CVH mice
exposed to linaclotide or saline run simultaneously. After
20 minutes of air drying, sections were ﬂushed 3 times
with PBS and incubated with 5% normal chicken serum/
0.2% Triton-X 200 (Sigma-Aldrich) in PBS (0.2% TX-PBS)
for 30 minutes at room temperature to block nonspeciﬁc
binding of secondary antibodies. Sections were then incu-
bated for 18 hours at room temperature with monoclonal
anti-sera rabbit anti-phospho-p44/42 MAPK (Erk1/2)
(Thr202/Tyr204) (pERK; 1:200; #4370; Cell Signaling
Technology, Danvers, MA) diluted in 0.2% TX-PBS. Sec-
tions were then washed 3 times with 0.2% TX-PBS before
being incubated for 1 hour at room temperature with
secondary antibody chicken anti-rabbit AlexaFluorR488
(AF-488). Negative controls were prepared as mentioned
here with the primary antibody omitted.13
Expression of GC-C in Mouse Tissue
Quantitative reverse transcription polymerase
chain reaction. Total RNAs from mouse peripheral tis-
sues were purchased from Clontech Laboratories. Brain
regions, dorsal root ganglion, esophagus, stomach, small
and large intestinal segments, bladder, and vaginal tissue
were collected from C57Bl6 mouse. Total RNA from these
tissues was extracted using Trizol (cat. no. 15596018; Life
Technologies, Carlsbad, CA) and further puriﬁed with the
RNeasy Mini Kit (cat. no. 74106; Qiagen, Valencia, CA).
Complementary DNAs were synthesized using a high-
capacity cDNA reverse transcription kit (cat. no.
4368813; Life Technologies) according to the manufac-
turer’s protocol (cms_04557; Life Technologies). Five
hundred nanograms of complementary DNA was used for
Taqman quantitative reverse transcription polymerase
chain reaction gene expression analysis. Mouse-speciﬁc
GC-C (Gucy2c) (cat. no. Mm01267705_m1; Life Tech-
nologies) and housekeeping glyceraldehyde-3-phosphate
dehydrogenase Taqman probes (cat. no. 4352339E; Life
Technologies) were obtained from Life Technologies. The
2-DDCt method was used to calculate relative messenger
RNA expression.14
GC-C Receptor In Situ Hybridization in Adult
Mouse Tissue
Tissue preparation and pretreatment. Tissues were
frozen in isopentane cooled to 35C. Cryostat sections,
610 mm, were mounted on gelatin-coated slides or
Fisherbrand Superfrost Plus slides (cat. no. 12-550-15;
Fisher Scientiﬁc, Waltham, MA) and stored at 80C.
Before in situ hybridization, sections were ﬁxed in 4%
formaldehyde (freshly made from paraformaldehyde;
P6148; Sigma Aldrich) in PBS, treated with triethanol-
amine/acetic anhydride, washed, and dehydrated in a se-
ries of ethanol washes. For distal gut tissues, the rectum
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(tissue up to 1 cm up from the anus) was dissected free
from the colon. The colon (from the cecum to the rectum)
was divided into 3 equally sized pieces and termed the
ascending, transverse, and descending colon, respectively.
Complementary RNA probe preparation. The
sequences of GC-C (Gucy2c Mus Musculus) primers were
obtained with PrimerQuest and positioned within exons
7 and 11 of the transcripts NM_001127318.1 and
NM_145067.3 (see Appendix) coding a fragment of 622 bp.
Forward primer: TTTGAGGAGAACACCACAGCTCCT
The T7 RNA polymerase recognition sequence
(T7 ¼ 50-GCGCTATAATACGACTCACTATAGGGA
GA-30) was included adjacent to the forward primer.
Reverse primer: TGATGTGGTTGGTCTCGTTGGTCT
The SP6 RNA polymerase recognition sequence
(SP6 ¼ 50-GCATTAATTTAGGTGACACTATAGAAG
CG-30) was included adjacent to the reverse primer. The
complementary RNA probe template was ampliﬁed by
polymerase chain reaction. Before in situ hybridization,
cold complementary RNA probes were produced in vitro
using SP6 and T7 RNA polymerases to verify if the
templates would yield probes of the appropriate length.
After successful validation, antisense and sense radio-
labeled probes were synthesized in vitro according to
manufacturer’s speciﬁcations (Ambion, Carlsbad, CA)
and labeled with 35S-UTP (>1000 Ci/mmol; cat. no.
NEG039H; PerkinElmer LAS Canada, Inc., Woodbridge,
Ontario, Canada).
Hybridization and washing procedures. Sections
were hybridized overnight at 55C in 50% deionized
formamide, 0.3 M NaCl, 20 mM Tris-HCl (pH 7.4), 5 mM
EDTA, 10 mM NaH2PO4, 10% dextran sulfate, 1 Den-
hardt’s, 50 mg/mL total yeast RNA, and 5080,000 cpm/mL
35S-labeled complementary RNA probe. The tissues were
subjected to stringent washing at 65C in 50% formamide,
2 standard saline citrate, 10mMdithiothreitol, andwashed
in PBS before treatment with 20 mg/mLRNAse A at 37C for
30 minutes. After washes in 2 standard saline citrate and
0.1 standard saline citrate for 10minutes at 37C, the slides
were dehydrated and exposed to Kodak BioMaxMR x-ray
ﬁlm for 5 days then dipped in Kodak NTB nuclear track
emulsion and exposed in light-tight boxes with desiccant at
4C for 14 days.
Imaging
Photographic development was carried out in
Kodak D-19 and ﬁxed in 35% sodium thiosulfate solution.
Sections were counterstained lightly with cresyl violet and
analyzed using brightﬁeld and darkﬁeld microscopy.
Sense (control) riboprobes established the level of back-
ground signal.
Contractility Studies
Colonic tissue from male Sprague-Dawley rats was
divided into 2-cm segments and transferred to an Schuler
Organ Bath. Colon segments were suspended in tissue
bath vessels containing Krebs solution (117.9 mmol/L
NaCl, 4.7 mmol/L KCl, 25 mmol/L NaHCO3, 1.3 mmol/L
NaH2PO4, 1.2 mmol/L MgSO4[H2O], 2.5 mmol/L CaCl2,
and 11.1 mmol/L D-glucose) continuously aerated with
95% O2, 5% CO2 and maintained at a temperature of 37C.
Tissue resting tension was 0.5 g. Colonic tissues were
stimulated at a ﬁxed frequency (8 Hz, 0.5-millisecond
duration, 10 V, 3 trains of 10-second width, with a
2-minute delay between trains). Two control stimulations
were performed and tissues were allowed to recover for 10
minutes. After the recovery period, tissues were treated
either with vehicle (n ¼ 6), linaclotide (1000 nM; n¼ 6), or
membrane permeable 8-bromo-cGMP (100 mM; n ¼ 6) at
a volume of 100 mL and electrical ﬁeld stimulation at the
ﬁxed frequency was repeated. Contraction amplitude is
expressed as percent baseline amplitude of the second set
of 8-Hz control stimulations. The amplitude of stimula-
tions before treatment is considered 100% amplitude.
Treatment with test article was initiated 5 minutes before
electrical ﬁeld simulation or pharmacological stimulation.
Data are expressed as the mean  SEM.
Basolateral cGMP Accumulation After
Linaclotide Activation of GC-C in Caco-2 Cells
Human cell line and culture reagents. The human
intestinal cell line, Caco-2, was acquired from American
Type Culture Collection (ATCC, Manassas, VA, catalog #
HTB-37 L/N 57850025). Dulbecco’s modiﬁed Eagle’s
medium, L-glutamine, and 0.25% trypsine-EDTA were
purchased from VWR (Bridgeport, NJ). Heat-inactivated
fetal bovine serum, nonessential amino acids solution,
Hank’s balanced salt solution, and hydroxyethylpiper-
azine-N0-2-ethanesulfonic acid were obtained from Gibco
(Grand Island, NY). Probenecid, cGMP, dimethyl sulf-
oxide, and collagen solution were purchased from Sigma-
Aldrich Inc.
Preparation of Caco-2 cell monolayers. Caco-2
cells were maintained in Dulbecco’s modiﬁed Eagle’s me-
dium containing 10% fetal bovine serum, 1% glutamine,
and 1% nonessential amino acids solution, in a humidiﬁed
atmosphere (37C  2C, 5%  1% CO2). The culture
medium was changed 3 times weekly, and the cell growth
was observed by light microscopy. When the cells reached
conﬂuency, they were harvested by trypsinization. The
collected cells were then seeded to collagen-coated poly-
ethylene terephthalate membrane inserts in 24-well plates
(0.33 cm2 insert area, 0.4-mm pore size; BD Biosciences,
San Jose, CA) to grow cell monolayers. The seeding density
was w2  104 cells per well. Plates were placed in a hu-
midiﬁed incubator (37C  2C, 5%  1% CO2), and the
culture medium was changed for each well every other day
until use. Cells cultured in the plates for 2128 days were
used. The transepithelial electric resistance was measured
to ensure monolayer integrity using an epithelial tissue
volt ohmmeter (World Precision Instruments Inc., Sar-
asota, FL). Cell monolayers with resistance values of >250
Ucm2 were used for experiments.
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cGMP efﬂux inhibition study. Caco-2 cell mono-
layers were ﬁrst washed twice with prewarmed transport
assay buffer at pH 7.0 for apical side and 7.4 for baso-
lateral side. The transport assay buffer was Hank’s balanced
salt solution containing 10 mM hydroxyethylpiperazine-N0-
2-ethanesulfonic acid and 15 mM glucose. Transport buffer
containing 1% dimethyl sulfoxide or transporter inhibitor
probenecid in dimethyl sulfoxide (1% ﬁnal concentration)
was added to both apical and basolateral chambers and
incubated at 37C. After 15-minute incubation, cells (in
triplicate) received treatments (Table 1) and were incubated
at 37C for 60 minutes.
After the treatments, 0.2-mL samples from basolateral
chambers were collected and cyclic GMP (cGMP) concen-
trations were determined by liquid chromatography mass
spectrometry. To determine the levels of intracellular cGMP
in the Caco-2 cells after treatments, cells were washed once
with transporter assay buffer and then lysed by treating
each well with 0.1 mL 0.1 M HCl on ice for 15 minutes,
followed by centrifugation to pellet cell debris. The result-
ing supernatants were transferred in 90-mL aliquots to 96-
well plates and neutralized with 90 mL of 1M ammonium
acetate. The centrifuged and neutralized (pH 7) Caco-2 cell
lysates and aliquot from the basolateral compartments were
analyzed using liquid chromatography mass spectrometry.
The method outlined in Table 2 was used to quantify the
concentration of cGMP in each sample. A standard curve of
cGMP was prepared in transporter buffer at pH 7.0 for
apical samples, at pH 7.4 for basolateral samples, and 0.1 M
HCl for cell lysates, followed by neutralization with an
equal volume of ammonium acetate, resulting in standards
ranging from 1 nM to 1024 nM.
Human Phase III Clinical Trials. This phase III,
double-blind, parallel-group, placebo-controlled trial ran-
domized 805 IBS-C patients to placebo or 290 mg of oral
linaclotide once daily for a 26-week treatment period. Trial
design and details have been published previously15
(Supplementary Figure 3) and conform to Consolidated
Standards of Reporting Trials guidelines (ClinicalTrials.
gov number: NCT00938717).
The current results are fromapost-hoc analysis of this trial
and are an efﬁcacy analysis based on a responder end point
for abdominal pain, speciﬁed as part of a co-primary end
point recommended in the May 2012 US Food and Drug
Administration ﬁnal guidance for industry on the clinical
evaluation of products for IBS,16 deﬁned as a 30%
improvement from baseline in average daily worst abdom-
inal pain score.16We present, for the ﬁrst time, an evaluation
of this abdominal pain responder end point for each week of
the 26-week treatment period, comparing treatment and
control groups. All authors had access to the study data and
had reviewed and approved the ﬁnal manuscript.
Trial Design
This 26-week, multicenter, randomized,
double-blind, placebo-controlled, parallel-group trial
was conducted at 102 clinical centers in the United
States between July 2009 (ﬁrst patient enrolled) and
September 2010 (last patient completed). The trial
was designed, conducted, and reported in compliance
with the principles of Good Clinical Practice guide-
lines. At each center, an informed consent form
approved by an Institutional Review Board was
reviewed and signed by all patients before their
participation in the trial.
During an initial screening period of up to 21 days,
patients provided blood and urine for routine testing
and were instructed to discontinue any prohibited
medications (eg, anticholinergics, narcotics) for at least
14 days (24 hours for nonsteroidal anti-inﬂammatory
drugs, if taken for abdominal pain, and for laxatives)
before the start of baseline assessments. Patients
meeting the inclusion and exclusion criteria then
entered the 14-day baseline period, during which they
used an interactive voice response system to provide
daily and weekly symptom assessments. Patients
eligible for the 26-week treatment period were ran-
domized (1:1) to receive 290 mg linaclotide or placebo,
administered as an oral capsule once daily at least 30
minutes before breakfast. This dose-strength designa-
tion reﬂects speciﬁc linaclotide content rather than the
total peptide content expressed in previously reported
studies, as linaclotide content is a more accurate and
precise indication of dose strength. The actual amount
of linaclotide received by patients did not change
throughout the trial.
In addition to a screening visit, study site visits
occurred at the start of the baseline period (day 14) and
throughout the treatment period (days 1, 15, 29, 57, 85,
113, 141, and 183). All personnel involved in the design
and implementation of the trial remained blinded until
the database was locked.
Trial Patients
Patients were men and women aged 18 years or
older who met modiﬁed Rome II criteria for IBS-C.15 In
the 12 months before the screening visit, eligible pa-
tients reported for at least 12 weeks (which need not be
consecutive) abdominal pain or abdominal discomfort
that had 2 of the following features: relief with defe-
cation; onset associated with a change in frequency of
stool; and/or onset associated with a change in form
(appearance) of stool, before starting chronic treatment
with tegaserod or lubiprostone (if patients had taken
these medications) and <3 spontaneous bowel move-
ments (SBMs, deﬁned as bowel movements [BMs]
occurring in the absence of laxative, enema, or suppos-
itory use during the 24 hours before the BM) per week
and 1 of the following symptoms: straining during
>25% of BMs, lumpy or hard stools during >25% of
BMs, and a sensation of incomplete evacuation during
>25% of BMs, before starting chronic treatment with
tegaserod, lubiprostone, polyethylene glycol 3350, or
any laxative (if patients had taken these medications). To
be eligible for randomization, patients had to report
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during the baseline period an average weekly score of3 for
daily abdominal pain at its worst (worst abdominal pain)
on an 11-point numeric rating scale (0 ¼ no abdominal
pain, 10 ¼ severe abdominal pain), and an average of <3
complete SBMs (deﬁned as SBMs accompanied by patient
self-reporting of a feeling of complete evacuation) per week
and 5 SBMs per week.
Exclusion criteria included the following: loose (mushy)
or watery stools reported in the absence of laxatives for
>25% of BMs during the 12 weeks preceding the trial;
mushy stool (Bristol Stool Form Scale14 score of 6) for >1
SBM, or a watery, liquid stool (Bristol Stool Form Scale
score of 7) for any SBM during the baseline period; a
history of surgery to remove a segment of the gastroin-
testinal tract or bariatric surgery for obesity at any time;
appendectomy/cholecystectomy within 2 months or other
abdominal operations within 6 months before entry into
the trial; history of diverticulitis or any chronic condition
that could be associated with abdominal pain or
discomfort and could confound the assessments in this
trial; or a history of laxative abuse. In general, patients
were excluded if they were taking drugs that could cause
constipation (eg, narcotics), however, patients taking
certain drugs for IBS that might be constipating (eg, tri-
cyclic antidepressants) were eligible, provided that they
were on a stable dose for at least 30 days before the
screening visit and there was no plan to change the dose
after the screening visit. Colonoscopy requirements were
based on the American Gastroenterological Association
guidelines.17
A total of 805 patients were randomized and received at
least 1 dose of trial medication. A total of 599 patients
completed the entire 26-week treatment period. The
treatment groups were well balanced with respect to de-
mographics and baseline bowel and abdominal symptoms,
with the exception that the placebo group had a greater
percentage of men than did the linaclotide group (12.7%
vs 8.2%). During the baseline period, 87% of patients
experienced abdominal pain every day and 76% of patients
had no complete SBMs. Mean compliance with study-
drug dosing (assessed by counting pills returned at
study visits) up to study discontinuation/completion
during the 26-week treatment period was 97.2% and 96.8%
for the placebo and linaclotide groups, respectively.
Efﬁcacy Assessments
Daily symptoms recorded using interactive voice
response system included worst abdominal pain
(measured using an 11-point numerical rating scale), the
number of BMs, and whether rescue medication (ie, per
protocol use of bisacodyl 5-mg tablets or suppositories)
was used. Each BM was assessed for sensation of complete
bowel emptying (yes/no).
The efﬁcacy assessments evaluated during the 26
weeks of treatment were the following: improvement of
30% from baseline in average daily worst abdominal
pain score and increase of 1 complete SBM from
baseline.
Statistical Methods and Data Analysis
Patients were randomized by a computer-generated
schedule to 1 of the 2 treatment groups (1:1) and were
balanced within each site using a block size of 4. The
sponsor staff, patients, and trial center personnel were
blinded to trial treatment allocation.
The overall family-wise type I error rate for testing the
primary efﬁcacy end points was controlled at the .05 sig-
niﬁcance level using a 5-step serial gate-keeping multiple
comparisons procedure.
All randomized patients who took at least 1 dose of
study drug were included in safety analyses (safety pop-
ulation). Efﬁcacy analyses were based on an intent-to-
treat population, which included all patients in the
safety population who had at least 1 post-randomization
efﬁcacy assessment (note: there was only 1 randomized
patient who was not included in this intent-to-treat
population).
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Linaclotide C C E Y C C N P A C T G C Y
Uroguanylin N D D C E L C V N V A C T G C L 
Guanylin P G T C E I C A Y A A C T G C
Supplementary Figure 1. Primary structures of linaclotide, human uroguanylin, and human guanylin. Identical amino acids are shaded by boxes. In
this study, human uroguanylin was applied to colonic nociceptors during in vitro recordings.
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Supplementary Figure 2. Linaclotide inhibits colonic nociceptor responses to high-intensity stretch. Application of linaclotide (1000 nM) to the
mucosal epithelium subsequently reduces nociceptor responsiveness to noxious circular stretch (11 g) when expressed as (A) spikes/s (***P < .001,
paired t test, n¼ 7) or (B) number of spikes/response (**P < .01, paired t test, n¼ 7). (C) (i) Single-unit extracellular recording showing action potential
discharge of a healthy mouse colonic nociceptor in response to 11 g circular stretch at baseline. (ii) Nociceptor responsiveness is reduced after 5
minutes application of linaclotide (1000 nM). Top panel shows the frequency of action potential ﬁring. Arrows indicate application and removal of the
11-g circular stretch.
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Supplementary Figure 3. Patient ﬂow through the phase III clinical trial. From Chey et al,15 adapted with permission.
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Table 1. Treatment Groups
Treatment
Apical chamber (pH 7.0) Basolateral chamber (pH 7.4)
Volume 0.3 mL Volume 1 mL
Control Vehicle only Vehicle only
Linaclotide 1 mM linaclotide Vehicle only
Linaclotide þ probenecid 1 mM linaclotide þ 0.5 mM probenecid 0.5 mM probenecid
Linaclotide þ probenecid 1 mM linaclotide þ 2 mM probenecid 2 mM probenecid
Table 2. Liquid Chromatography Mass Spectrometry Method for Quantitative Determination of Cyclic GMP
HPLC Waters Acquity UPLC
Column Hypersil Gold C18, 2.1  50 mm, 1.9 mm
Guard column Hypersil Gold, 2.1  10 mm, 1.9 mm
Flow rate 400 mL/min
Column temperature Room temperature
Autosampler temperature 6C
Injection volume 10 mL
Mobile phases A ¼ 0.1% formic acid in 98/2 water/acetonitrile
B ¼ 0.1% formic acid in 2/98 water/acetonitrile
Gradient Time, min A, % B, %
0 100 0
0.5 60 40
1.1 60 40
1.75 5 95
2.5 5 9
2.6 100 0
Mass spectrograph Thermo quantum
Ion mode Electrospray ionization, positive mode
Scan type Multiple reaction monitoring
Compound: cyclic GMP Transition Dwell time, ms Collision energy, V Tube lens Retention time, min LLOQ, nM
346 > 152 100 28 139 0.8 1
ESI, Electrospray ionisation; HPLC, High performance liquid chromatography; LLOQ, Lower Limit of Quantiﬁcation.
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